| pubmed-article:10027856 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10027856 | lifeskim:mentions | umls-concept:C0011616 | lld:lifeskim |
| pubmed-article:10027856 | lifeskim:mentions | umls-concept:C0020517 | lld:lifeskim |
| pubmed-article:10027856 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:10027856 | lifeskim:mentions | umls-concept:C0035804 | lld:lifeskim |
| pubmed-article:10027856 | lifeskim:mentions | umls-concept:C1709060 | lld:lifeskim |
| pubmed-article:10027856 | lifeskim:mentions | umls-concept:C0205421 | lld:lifeskim |
| pubmed-article:10027856 | lifeskim:mentions | umls-concept:C0596448 | lld:lifeskim |
| pubmed-article:10027856 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:10027856 | pubmed:dateCreated | 1999-4-1 | lld:pubmed |
| pubmed-article:10027856 | pubmed:abstractText | Oral N-acetyl-L-cysteine (NAC) is used clinically for treatment of chronic obstructive pulmonary disease. NAC is easily oxidized to its disulfide. We show here that N,N'-diacetyl-L-cystine (DiNAC) is a potent modulator of contact sensitivity (CS)/delayed type hypersensitivity (DTH) reactions in rodents. Oral treatment of BALB/c mice with 0.003 to 30 micromol/kg DiNAC leads to enhancement of a CS reaction to oxazolone; DiNAC is 100 to 1000 times more potent than NAC in this respect, indicating that it does not act as a prodrug of NAC. Structure-activity studies suggest that a stereochemically-defined disulfide element is needed for activity. The DiNAC-induced enhancement of the CS reaction is counteracted by simultaneous NAC-treatment; in contrast, the CS reaction is even more enhanced in animals treated with DiNAC together with the glutathione-depleting agent buthionine sulfoximine. These data suggest that DiNAC acts via redox processes. Immunohistochemically, ear specimens from oxazolone-sensitized and -challenged BALB/c mice treated with DiNAC display increased numbers of CD8(+) cells. DiNAC treatment augments the CS reaction also when fluorescein isothiocyanate is used as a sensitizer in BALB/c mice; this is a purported TH2 type of response. However, when dinitrofluorobenzene is used as a sensitizer, inducing a purported TH1 type of response, DiNAC treatment reduces the reaction. Treatment with DiNAC also reduces a DTH footpad-swelling reaction to methylated BSA. Collectively, these data indicate that DiNAC in vivo acts as a potent and effective immunomodulator that can either enhance or reduce the CS or DTH response depending on the experimental conditions. | lld:pubmed |
| pubmed-article:10027856 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10027856 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10027856 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10027856 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10027856 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:10027856 | pubmed:author | pubmed-author:BergstrandHH | lld:pubmed |
| pubmed-article:10027856 | pubmed:author | pubmed-author:ScheyniusAA | lld:pubmed |
| pubmed-article:10027856 | pubmed:author | pubmed-author:SärnstrandBB | lld:pubmed |
| pubmed-article:10027856 | pubmed:author | pubmed-author:PierronJJ | lld:pubmed |
| pubmed-article:10027856 | pubmed:author | pubmed-author:Matuseviciene... | lld:pubmed |
| pubmed-article:10027856 | pubmed:author | pubmed-author:JanssonA HAH | lld:pubmed |
| pubmed-article:10027856 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10027856 | pubmed:volume | 288 | lld:pubmed |
| pubmed-article:10027856 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10027856 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10027856 | pubmed:pagination | 1174-84 | lld:pubmed |
| pubmed-article:10027856 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:meshHeading | pubmed-meshheading:10027856... | lld:pubmed |
| pubmed-article:10027856 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10027856 | pubmed:articleTitle | N,N'-Diacetyl-L-cystine-the disulfide dimer of N-acetylcysteine-is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. | lld:pubmed |
| pubmed-article:10027856 | pubmed:affiliation | Department of Pharmacology, Astra Draco AB, Lund, Sweden. | lld:pubmed |
| pubmed-article:10027856 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10027856 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10027856 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10027856 | lld:pubmed |
